EASD
Refine Search
Biotechnology
Adocia has announced details of five abstracts to be presented at the upcoming annual meeting of the European Association for the Study of Diabetes (EASD). 27 September 2018
Biotechnology
UK biopharma company Arecor has raised £6 million ($7.8 million) from new and existing investors to develop groundbreaking pharmaceutical drugs to transform the treatment of diabetes. 10 September 2018
Pharmaceutical
Anglo-Swedish pharma major AstraZeneca announced positive results from the Phase III DURATION-8 trial, which demonstrated that its Bydureon (exenatide extended-release) for injectable suspension 2mg once-weekly in combination with Farxiga (dapagliflozin) 10mg once-daily significantly reduced blood sugar as measured by HbA1c, versus the individual medicines alone in patients with type 2 diabetes inadequately controlled on metformin. 17 September 2016
Pharmaceutical
Novo Nordisk has presented promising data both on a Phase III drug and an existing product at the Annual Meeting of the European Association for the Study of Diabetes (EASD) 2016. 16 September 2016
Pharmaceutical
Merck & Co in partnership with its peer Pfizer announced that a Phase III study (VERTIS SITA2) of ertugliflozin, an investigational oral SGLT2 inhibitor for the treatment of patients with type 2 diabetes, met its primary endpoint. 15 September 2016
Pharmaceutical
Sanofi has presented new data suggesting that a fixed-ratio combination of lixisenatide and insulin glargine, known as iGlarLixi, helps more diabetes patients with type 2 diabetes to reach mealtime blood sugar targets than insulin glargine alone. 15 September 2016
Pharmaceutical
The 52nd Annual Meeting of the European Association for the Study of Diabetes (EASD) is now taking place in Munich, Germany, and included some notable new data presentations. 13 September 2016
Pharmaceutical
Innovent Biologics has announced positive results from a Phase III trial for mazdutide, a dual agonist targeting GLP-1 and glucagon receptor. 12 September 2024
Pharmaceutical
Novo Nordisk has announced that its obesity drug Saxenda (liraglutide) has been shown to be safe and effective in treating obesity in children aged 6-12 years, based on results from a Phase IIIa trial. 12 September 2024
Pharmaceutical
Lexicon Pharmaceuticals has released new data from a Phase III trial showing that its drug sotagliflozin improves certain glucose control parameters in people with type 2 diabetes. 12 September 2024
Generics
Russian drugmaker Geropharm once again failed to challenge the patent for Toujeo (long-acting insulin glargine) produced by the French pharma major Sanofi, reports The Pharma Letter’s local correspondent. 5 September 2023
Pharmaceutical
In a bid to consolidate its lead in the weight management therapy sector, diabetes care giant Novo Nordisk has now bought a fellow Denmark based company and its obesity program. 30 August 2023
Biotechnology
The US Food and Drug Administration yesterday approved Lantidra (donislecel), the first allogeneic (donor) pancreatic islet cellular therapy made from deceased donor pancreatic cells for the treatment of type 1 diabetes. 30 June 2023
Pharmaceutical
Mounjaro (tirzepatide) has not been recommended in draft guidance issued by the National Institute for Health and Care Excellence (NICE) on Tuesday for treating type 2 diabetes in adults alongside diet and exercise. 27 June 2023
Pharmaceutical
Pharma giant Pfizer was trading 4% lower at lunchtime on Monday. 26 June 2023
Pharmaceutical
More data from Novo Nordisk’s ONWARDS program show positive results for the firm’s new once-weekly insulin product, insulin icodec. 22 September 2022
Pharmaceutical
According to new data from the CONCLUDE head-to-head trial, Tresiba (insulin degludec) showed an overall lower risk of hypoglycemia, also known as a hypo or low blood sugar, at a significantly lower HbA1c, compared with insulin glargine U300 in adults with type 2 diabetes uncontrolled on basal insulin with or without oral anti-diabetic drugs (OADs). 19 September 2019
Biotechnology
Data presented in a symposium session at the annual meeting of the European Association for the Study of Diabetes (EASD) provide insights into imeglimin, an investigational type 2 diabetes medicine. 18 September 2019
Pharmaceutical
Eisai has presented data showing the potential of its anti-obesity drug Belviq (lorcaserin hydrochloride) to prevent and cause remission of type 2 diabetes. 5 October 2018
Pharmaceutical
Germany’s Boehringer Ingelheim and the USA’s Eli Lilly have presented positive long-term results from the CARMELINA trial of Tradjenta (linagliptin) at the annual meeting of the European Association for the Study of Diabetes, in Berlin. 5 October 2018
Pharmaceutical
Boehringer Ingelheim and Eli Lilly announced today that empagliflozin met the primary efficacy endpoint, defined as a change from baseline in A1C versus placebo after 26 weeks of treatment, for all doses investigated (2.5, 10 and 25 mg) in the Empagliflozin as Adjunctive to inSulin thErapy (EASE) Phase III program in adults with type 1 diabetes. 4 October 2018
Pharmaceutical
Six month Phase II data on Eli Lilly’s dual GIP and GLP-1 receptor agonist, LY3298176, show “clinically meaningful blood sugar reduction and weight loss” in people with type 2 diabetes, the firm says. 4 October 2018
Biotechnology
At EASD 2018, The Pharma Letter spoke with Novo Nordisk’s chief medical officer Stephen Gough Mads Krogsgaard Thomsen about recent job losses at the company, and the seismic potential of oral semaglutide. 2 October 2018
Biotechnology
London-listed GlaxoSmithKline has presented positive data from the Harmony Outcomes study at the European Association for the Study of Diabetes. 2 October 2018
Pharmaceutical
The 54th annual meeting of the European Association for the Study of Diabetes kicks off in Berlin today, offering a week of data presentations from leading drugmakers in the diabetes space. 2 October 2018
Pharmaceutical
At its annual meeting in Berlin, the European Association for the Study of Diabetes (EASD) has launched a new initiative, aimed at enabling “the sustainability of European healthcare systems to cope with the diabetes pandemic.” 2 October 2018
Biotechnology
Texan drugmaker Lexicon Pharmaceuticals has announced details of clinical data for oral diabetes therapy sotagliflozin, to be presented at the upcoming annual meeting of the European Association for the Study of Diabetes (EASD). 27 September 2018
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze